Skip to main content
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Publisher: Bentham Science Publishers

More about this publication?
Volume 14, Number 6, 2014

Articles

Graphical Abstract:
pp. i-iv(4)

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
pp. 537-548(12)
Authors: Miller, Zachary; Lee, Wooin; Bo Kim, Kyung

Favourites:
ADD

NEDD4: A Promising Target for Cancer Therapy
pp. 549-556(8)
Authors: Ye, Xiantao; Wang, Lixia; Shang, Bingxue; Wang, Zhiwei; Wei, Wenyi

Favourites:
ADD

Arsenic Trioxide Exerts Anti-lung Cancer Activity by Inhibiting Angiogenesis
pp. 557-566(10)
Authors: Yang, Meng-Hang; Zang, Yuan-Sheng; Huang, Hai; Chen, Kun; Li, Bing; Sun, Guang-Yuan; Zhao, Xue-Wei

Favourites:
ADD

Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
pp. 567-588(22)
Authors: Huang, Wen-Qing; Lin, Qing; Zhuang, Xuan; Cai, Liang-Liang; Ruan, Run-Sheng; Lu, Zhong-Xian; Tzeng, Chi-Meng

Favourites:
ADD

Efficacy and Safety of Combined Radiotherapy with EGFR Inhibitors and Chemotherapy for Laryngeal Organ Preservation in Patients with Locally Advanced Hypopharyngeal Carcinomas
pp. 589-598(10)
Authors: Zhang, Xinxin; Wang, Jailing; Wu, Wenming; Liu, Mingbo; Zhao, Feifang; Du, Lei; Huang, Deliang; Yang, Shiming; Ma, Lin

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content